News Releases

16 Dec '21
Alvotech received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15. The centralized marketing authorization in the European Union (EU) follows the recommendation of the Committee for Medicinal Products
08 Oct '21
U.S. Federal Judge Grants Alvotech’s Motion to Dismiss AbbVie’s lawsuit alleging misappropriation of trade secrets. A U.S. federal judge has dismissed a lawsuit brought by AbbVie against Alvotech Hf alleging theft of trade secrets. Alvotech, is seeking to bring an affordable high-concentration
25 Jun '21
Funds provide additional resources and runway for advancing the company's biosimilar pipeline. Reykjavik, Iceland June 24, 2021  – Alvotech Holdings SA today announced that it has entered into an amendment and restatement agreement with bondholders of its $300m convertible bond issued on December
Displaying 71 - 80 of 109